The Ibn Sina Pharmaceutical Industry PLC introduces Dexlan MUPS 30 mg, an advanced Dual Delayed-Release (DDR) Multi-Unit Pellet System designed for superior, 24-hour acid control in patients with symptomatic non-erosive GERD and maintained healing of Erosive Esophagitis. Engineered with uniform micro-pellets, Dexlan MUPS disintegrates rapidly in the stomach to prevent localized mucosa irritation and dose-dumping, delivering a biphasic release profile that guarantees consistent plasma concentrations regardless of meal timing. Positioned as a hassle-free, highly predictable step-down and maintenance therapy, this once-daily formulation offers clinicians an optimized option for long-term GERD management with maximum patient compliance and round-the-clock symptom relief.
